Dow AgroSciences, Dualsystems Biotech Announce Profiling Agreement

INDIANAPOLIS & ZÜRICH--()--Dow AgroSciences LLC, a wholly owned subsidiary of The Dow Chemical Company (NYSE: DOW), and Dualsystems Biotech announced today, a drug profiling agreement. Under the agreement, Dualsystems Biotech will use its drug profiling platform to identify molecular targets for an undisclosed small molecule lead candidate in Dow AgroSciences’ agrochemical discovery program. Dualsystems Biotech as a partner will contribute to the identification of new targets and elucidation of the mechanism of action of a novel class of compounds.

Dualsystems exploits the versatility of its platform technology by continuously expanding its international client base into all sectors of the life science industry.

“Dow AgroSciences is pleased to announce this new partnership with Dualsystems, an innovative leader in custom screening services,” said Vidyadhar B. Hegde, Ph.D., Director, Chemistry, Discovery Research, Dow AgroSciences. “This collaboration further expands our technology tool-box to accelerate the progress of Discovery efforts to develop novel solutions to meet the growing demands of our customers around the world.”

“As we offer our superior services in a highly competitive research area we are proud to have won this agreement from a prominent leader such as Dow AgroSciences,” said Daniel Auerbach, CEO – Operations, Dualsystems Biotech.

About Dualsystems Biotech AG

Dualsystems Biotech is a privately held biotechnology company established in 2006 as a spin-off from the University Zurich, Switzerland. Dualsystems has positioned itself as a leading provider of screening services to the international research community in the pharmaceutical, biotech, agrochemical and cosmetic industries as well as academia.

Dualsystems Biotech’s unique and comprehensive screening platforms enable the identification of small molecule-protein and protein-protein interactions in any cellular setting. Dualsystems Biotech’s drug and target profiling technologies have significant advantages in cost, speed and sensitivity compared to similar screening technologies for small molecules currently available. They are a powerful tool to accelerate drug target discovery and elucidation of mechanism of action and off-target effect identification in key therapeutic areas.

For more information about Dualsystems Biotech please visit http://www.dualsystems.com/ or http://www.drug-profiling.com

About Dow AgroSciences

Dow AgroSciences, based in Indianapolis, Indiana, USA, develops leading-edge crop protection and plant biotechnology solutions to meet the challenges of the growing world. Dow AgroSciences is a wholly owned subsidiary of The Dow Chemical Company and had annual global sales of $5.7 billion in 2011. Learn more at www.dowagro.com. Follow Dow AgroSciences on Facebook and YouTube or subscribe to our News Release RSS Feed.

Contacts

Dow AgroSciences
Robyn Heine, 317-337-4807
rheine@dow.com
or
Dualsystems Biotech AG
Dr. Andreas J. Schulze, +41 44 738 50 01
Fax: +41 44 738 50 05
andreas.schulze@dualsystems.com

Release Summary

Dow AgroSciences LLC and Dualsystems Biotech announced today, a drug profiling agreement.

Contacts

Dow AgroSciences
Robyn Heine, 317-337-4807
rheine@dow.com
or
Dualsystems Biotech AG
Dr. Andreas J. Schulze, +41 44 738 50 01
Fax: +41 44 738 50 05
andreas.schulze@dualsystems.com